Gitnux/Report 2026

Biotechnology and Pharmaceutical Industry Statistics

302Statistics
103Sources
12Sections
1Visuals
51mRead
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The biotechnology and pharmaceutical industry at a glance

Biotechnology and pharmaceuticals remain a high-investment, innovation-led industry: the largest pharmaceutical companies reported more than $190 billion in R&D spending in 2024, equal to 25.2% of sales.

$1.55T[92]
Biotechnology market, 2023
13.96%[92]
Biotechnology CAGR, 2024–2030
$190B[59]
Large-pharma R&D spending, 2024
54.8%[67]
U.S. share of global drug sales, 2024
Market size
The global biotechnology market was estimated at $1.55 trillion in 2023. In Europe, the pharmaceutical market at factory prices was estimated at €295 billion in 2024, up from €274.5 billion in 2023.[92]
Forecast & CAGR
Grand View Research forecasts the global biotechnology market to reach $3.88 trillion by 2030, representing a 13.96% CAGR from 2024 to 2030. The forecast reflects continued expansion across biopharmaceuticals, agricultural biotechnology, industrial biotechnology and related applications.[92]
Market share & regions
The United States accounted for 54.8% of global pharmaceutical sales in 2024, ahead of Europe, China and Japan. Europe’s pharmaceutical manufacturing value was estimated at €440 billion in 2024, while exports reached €705 billion.[67]
Segmentation
The industry spans small-molecule medicines, biologics, biosimilars, vaccines, cell and gene therapies, diagnostics and biotechnology platforms. In 2025, the FDA’s Center for Drug Evaluation and Research approved 46 novel drugs: 34 new molecular entities and 12 biologics; it also approved 18 biosimilars.[25]
Key players & concentration
Large multinational pharmaceutical companies remain central to industry investment and commercialization. Fifteen major companies—including AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi and Takeda—reported more than $190 billion in combined R&D spending in 2024.[59]
Trends, drivers & challenges
Growth is being driven by high-value biologics, oncology, metabolic disease treatments, precision medicine and platform technologies, while companies face rising development costs, pricing pressure and regulatory uncertainty. IQVIA reported that large-pharma R&D intensity reached a record 25.2% of sales in 2024, indicating stronger investment but also heavier innovation costs.[59][93]
Consumer behavior & competition
Competition is increasingly concentrated around therapies for oncology, obesity and metabolic disease, neurology and immunology. In 2025, oncology accounted for 25% of the number of large biopharma deals and 32% of their value, while more than half of tracked deals still involved small molecules.[94]
M&A
Biopharma M&A rebounded in 2025: IQVIA recorded 50 M&A deals worth $133 billion, more than double the 2024 value. Licensing also expanded, reaching a 10-year high of $232 billion in total deal value.[2]
Regulation
U.S. regulation remains a major commercialization gatekeeper. In 2025, FDA CDER approved 46 novel drugs, including 23 treatments for rare or orphan diseases, and issued 19 complete-response letters for 18 novel-drug applications.[25]
Latest news
The latest industry outlook points to renewed dealmaking momentum in 2026 after a strong 2025. EY reported $240 billion in life-sciences M&A deals signed in 2025, with deal volume down 12% year over year but total value up 81%, as companies prioritized larger, later-stage or strategically important assets.[27]
report visual · Projection

Value of sold production of basic pharmaceutical products (European Union, excluding Cyprus, Luxembourg and Malta)

Value of sold production of basic pharmaceutical products grew from €23.1B in 2015 to €74.5B in 2025.

23.1B EUR
Start
+12.42%
CAGR · 10y
74.5B EUR
Projected
20152025
source-verifiedec.europa.eu2025

02 Ranking

Top 10 Companies in the Biotechnology And Pharmaceutical Industry

The leading companies in the biotechnology and pharmaceutical industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

Eli Lilly and Company leads Gitnux's 2026 biotechnology and pharmaceutical ranking with an Overall score of 9.8, with 2025 revenue reached $65.2 billion, driven by Mounjaro and Zepbound. Roche is the highest-ranked pharmaceuticals and diagnostics provider at 9.3, with 2025 group sales of CHF 61.5 billion across pharmaceuticals and diagnostics.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in innovative medicines

    Eli Lilly and Company

    US

    Ranked #1 · 9.8 · Innovative medicines

    Why we picked it: It sells innovative medicines and biologics at large global scale, supported by $65.2 billion 2025 revenue.

    See in ranking ↓Visit lilly.com ↗

  2. Leader in pharmaceuticals & diagnostics

    Roche

    CH

    Ranked #2 · 9.3 · Pharmaceuticals & diagnostics

    Why we picked it: Its dual pharma-and-diagnostics model is reflected in CHF 61.5 billion 2025 group sales.

    See in ranking ↓Visit roche.com ↗

  3. #3 overall

    Novo Nordisk

    DK

    Ranked #3 · 9.2 · Innovative medicines

    Why we picked it: Its diabetes and obesity franchise is measured by reaching 45.6 million people in 2025.

    See in ranking ↓Visit novonordisk.com ↗

Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.

Full ranking

Sort by
Top 10 companies in the biotechnology and pharmaceutical industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Innovative medicines · US

9.8
2

Roche

Pharmaceuticals & diagnostics · CH

9.3
3

Novo Nordisk

Innovative medicines · DK

9.2
4

Novartis

Innovative medicines · CH

9.2
5

AstraZeneca

Innovative medicines · GB

9.1
6

Johnson & Johnson

Pharmaceuticals and medical technologies, global · US

9.1
7

Sanofi

Vaccines, specialty care and medicines · FR

8.8
8

Pfizer

Biopharmaceuticals and vaccines, global · US

8.7
9

AbbVie

Immunology, oncology and specialty medicines · US

8.7
10

Bristol Myers Squibb

Biopharmaceuticals, oncology and immunology · US

8.6

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 10). Top 10 companies in the biotechnology and pharmaceutical industry. In Biotechnology And Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/biotechnology-and-pharmaceutical-industry-statistics/#top-companies

04 Statistics

Technology & Innovation

AI adoption is now mainstream in biopharma outlooks: 71% of executives said AI deployment advanced at least somewhat over the prior six months.

AI in the biotechnology and pharmaceutical industry

  • 71% of biopharma and medtech executives said AI deployment had advanced at least somewhat over the previous six months in the 2026 outlook survey.[1]
  • 78% of biopharma and medtech leaders expected AI to play a central role in driving major organizational change in 2026.[1]
  • 29% of biopharma leaders planned to use AI tools or training to improve workforce productivity in 2026.[1]
  • 58% of life-sciences commercialization leaders reported achieving at least 2x return on investment from AI initiatives within one year in a 2025 survey.[2]
  • 45% of biopharma and medtech executives said AI initiatives had produced measurable improvement, including 13% reporting measurable improvements at scale, in 2026.[1]
  • 60% of pharmaceutical executives had launched generative-AI pilots and 32% were scaling them across functions such as R&D, quality and regulatory in 2024.[3]

Automation in the biotechnology and pharmaceutical industry

  • 25% of pharmaceutical companies purchased drug-safety platforms and 20% built them internally in 2025.[3]
  • More than half of pharmaceutical companies used a compose strategy to build drug-safety platforms in 2025.[3]
  • 45% of resources used to build and maintain pharmaceutical drug-safety platforms came from external resources in 2025.[3]
  • 72% of pharmaceutical and life-sciences operations and supply-chain leaders said AI automation was driving greater reliance on real-time data for decision-making in 2026.[3]
  • 73% of pharmaceutical and life-sciences executives reported that automation was shifting employees into analytical and supervisory roles in 2026.[3]
  • 57% of pharmaceutical and life-sciences executives said they were comfortable assigning AI agents to detect anomalies and trigger corrective actions in 2026.[3]

Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)

  • 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[4]
  • 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[5]
  • 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[6]
  • 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[4]
  • 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[5]

Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)

  • 70% of global biopharma respondents had adopted an R&D data platform in 2023.[7]
  • 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[7]
  • 55% of biopharma AI adopters reported using AI in process development in 2024.[8]
  • 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[9]
  • 63% of global biopharma respondents had adopted robotics and automation in 2023.[7]

Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)

  • 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[8]
  • 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[7]
  • 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[10]
  • 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[1]
  • 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[8]

Big Data in the pharmaceuticals and biotech sector (sector benchmark)

  • 55% of large pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[6]
  • 49% of clinical-research survey respondents reported using AI and big-data analytics in drug development in 2024.[4]
  • 43% of small and midsize pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[6]

05 Statistics

Data & Analytics

Commercial AI scaling is constrained by structure and quality: 96% of U.S., Europe, and Asia-Pacific commercial leaders said data was not well-structured or AI-ready in 2025.

Business intelligence in the biotechnology and pharmaceutical industry

  • 49% of pharmaceutical and biotech medical-affairs professionals used analytics software in 2023.[11]
  • 8% of pharmaceutical and biotech medical-affairs professionals said their insight-generation process was highly automated in 2023.[11]
  • 58% of pharmaceutical and biotech medical-affairs professionals used data-visualization products in 2023.[11]
  • 61% of pharmaceutical and biotech medical-affairs professionals used technology to collect data for generating insights in 2023.[11]
  • 76% of pharmaceutical commercial respondents relied on consulting agencies for business insights and data analytics in a 2024 survey.[12]
  • 47% of pharmaceutical and biotech medical-affairs professionals surveyed used business-intelligence platforms in 2023.[11]

Data analytics in the biotechnology and pharmaceutical industry

  • 32% of biopharmaceutical leaders ranked data analytics, artificial intelligence and machine learning among their top three disruptive technology priorities for the next 12 months.[13]
  • 42% of large-pharmaceutical executives identified data analytics, artificial intelligence and machine learning as a technology priority.[13]
  • 30% of pharma marketers surveyed were evaluating artificial-intelligence technology, platforms or resources in 2024.[14]
  • 43% of small and midsize biopharma companies surveyed were pursuing big data and analytics or data science.[6]
  • 58% of pharma marketers surveyed were actively using artificial-intelligence technology, platforms or resources in commercial or clinical research.[14]
  • 55% of large biopharma companies surveyed were pursuing big data and analytics or data science.[6]

Data Quality in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[15]
  • Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[15]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[15]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[15]
  • Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[16]

Data Governance in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[17]
  • Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[16]
  • Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[17]
  • Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[18]
  • Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[17]

KPIs in the biotechnology and pharmaceutical industry

  • Revenue, market share, profitability and total prescriptions were the four leading metrics used to measure pharmaceutical commercialization-model success in 2023.[19]
  • 61% of surveyed pharmaceutical companies differentiated between metrics and KPIs in 2024.[20]
  • 55% of surveyed pharmaceutical companies reported escalation rate as a KPI in 2024.[20]
  • 65% of surveyed pharmaceutical companies reported the number of documents created or updated as a KPI in 2024.[20]
  • 77% of surveyed pharmaceutical companies reported response turnaround time as a KPI to senior leadership in 2024.[20]
  • 43% of biopharma launch leaders identified misalignment on KPIs or definitions of success as a challenge during their most recent launch.[15]

06 Statistics

Strategy & Growth

Investment and product mix continue shifting toward advanced therapies and late-stage assets, with advanced therapies at more than 40% of sales in 2024.

Growth in the biotechnology and pharmaceutical industry

  • North American pharmaceutical sales are projected to reach $853.1 billion in 2028.[21]
  • Global therapeutic-antibody sales exceeded $267 billion in 2024.[22]
  • Advanced therapies increased their share of overall pharmaceutical sales from 30% in 2018 to more than 40% in 2024.[22]
  • Greenfield advanced-pharmaceuticals manufacturing announcements totaled about $180 billion in 2025, up from about $18 billion in 2024.[22]
  • Latin America is projected to grow 14.3% from 2023 to 2028 in AstraZeneca’s pharmaceutical-market outlook.[21]
  • Emerging-market pharmaceutical sales are projected to reach $318 billion in 2024 under AstraZeneca’s market classification.[23]

Differentiation in the biotechnology and pharmaceutical industry

  • Macromolecules represented 48.1% of global first-in-class drugs approved during January 2023–October 2024.[24]
  • More than 40% of overall pharmaceutical sales came from advanced therapies in 2024.[22]
  • Only 6 of 99 oncology approvals with reported race data had trial participation by Black patients of at least 10%, highlighting a differentiation gap in inclusive development.[24]
  • 50 novel drug therapies were approved by the FDA’s Center for Drug Evaluation and Research in 2024.[25]
  • Monoclonal antibodies generated more than $267 billion in global therapeutic sales in 2024.[22]
  • 57 new therapeutic drugs were approved by FDA CDER and CBER in 2024 under a broader definition of new therapeutic drugs.[26]

Mergers and acquisitions in the biotechnology and pharmaceutical industry

  • 51% of 2024 biopharma deals targeted assets before Phase III, according to EY’s annual M&A analysis.[27]
  • Vertex agreed to acquire Alpine Immune Sciences for $4.9 billion in 2024, the largest biotech deal by upfront payment cited in the industry review.[28]
  • Novo Holdings’ acquisition of Catalent and related manufacturing facilities was valued at $16.7 billion in 2024.[28]
  • Biopharma-services M&A totaled $24.2 billion in 2024, compared with $20.5 billion in 2023.[29]
  • Small-molecule therapies accounted for 42 biopharma M&A deals worth $23.8 billion in 2024.[30]
  • Global life-sciences M&A investment totaled $130 billion in 2024, down 41% from $222 billion in 2023.[27]

Strategic partnerships in the biotechnology and pharmaceutical industry

  • Genetic medicines represented 9% of biopharma partnerships in 2024.[31]
  • AviadoBio granted Astellas a worldwide option potentially worth $2.23 billion for AVB-101 in October 2024.[26]
  • Takeda’s ACI-24.060 alliance covered an anti-amyloid-beta active immunotherapy candidate for Alzheimer’s disease in 2024.[26]
  • Novartis expanded its PeptiDream peptide-discovery collaboration to a potential value of $2.89 billion in 2024.[26]
  • The upfront payment in the AC Immune–Takeda ACI-24.060 alliance was $100 million in 2024.[26]
  • Overall biopharma partnership activity rebounded in 2024 as pharmaceutical companies shifted toward partnering.[31]

07 Statistics

People & Workforce

Work roles are changing alongside automation: 73% of pharmaceutical and life-sciences executives said automation shifted employees toward analytical and supervisory roles in 2026.

Hiring in the biotechnology and pharmaceutical industry

  • 64% of biopharma workforce-planning professionals said their organizations were actively recruiting in late 2025, up from 59% in 2024.[32]
  • AI was the technical skill most frequently identified as being in high demand by biopharma workforce-planning respondents for 2026.[32]

Employee retention in the biotechnology and pharmaceutical industry

  • 52% of pharmaceutical manufacturing professionals expected industry conditions to remain unchanged in 2026.[33]
  • 90.7% was PharmaEssentia’s average global employee retention rate in 2024.[34]
  • 16% of pharmaceutical manufacturing professionals were satisfied with their salary in the 2025 survey.[33]
  • 25% of pharmaceutical manufacturing professionals felt less secure in their jobs in the 2025 survey.[33]

Remote Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[35]
  • Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[35]
  • Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[36]
  • Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[37]

Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[38]
  • Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[36]
  • Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[39]
  • Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[40]

Upskilling in the biotechnology and pharmaceutical industry

  • 73% of pharmaceutical and life-sciences executives said automation was shifting employees toward analytical and supervisory roles in 2026.[3]
  • Digital skills gaps were identified as a continuing challenge for pharmaceutical manufacturing employers in the 2025 survey.[33]
  • Training perceptions among pharmaceutical manufacturing professionals improved in the 2025 survey, although digital-skills gaps remained.[33]

Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)

  • At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[41]
  • Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[42]
  • Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[42]
  • Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[42]

DEI in the biotechnology and pharmaceutical industry

  • 66% of Massachusetts life-sciences graduates were women in 2023.[39]
  • 18.7% of biotech chief executive officers were women in 2025.[43]
  • 33% of Massachusetts biopharma board members were women in 2023, up from 24% in 2021.[39]
  • 34% of biotech chief business officer roles were held by women in 2025.[43]
  • 53% of entry-level life-sciences respondents were women in the 2024 BioSpace DEIB report.[44]

Change Management in the pharmaceuticals and biotech sector (sector benchmark)

  • Among pharmaceutical and biotechnology executives surveyed, 26% expected to conduct a significant acquisition within the following 12 months in 2023.[45]
  • Across pharmaceutical-company respondents, organizations spent almost 14 months planning and initiating clinical-trial innovations before later evaluation, adoption, and implementation stages in 2022.[46]
  • Among pharmaceutical and biotechnology executives surveyed, 67% said their companies were using mergers and acquisitions to access talent or innovation in 2023.[45]
  • Among pharmaceutical and biotechnology executives surveyed, 69% felt their organizations were well equipped to handle growing pressures in 2023.[45]

08 Statistics

Customer & Sales

Customer engagement metrics stay mixed across channels, including a 65% bounce rate for healthcare-professional portals operated by pharmaceutical companies in 2024.

Customer experience in the biotechnology and pharmaceutical industry

  • -57% was the lowest pharmaceutical-company Net Promoter Score recorded among U.S. healthcare providers in 2025.[47]
  • -10% was the average Net Promoter Score for pharmaceutical companies among more than 700 U.S. healthcare providers surveyed in 2025.[47]
  • 58 was the global pharmaceutical-industry Customer Experience Quotient score in 2024.[4]
  • 82% of life-sciences executives said they were satisfied with their customer-engagement strategies, compared with 28% of healthcare professionals.[1]
  • 26% was the highest pharmaceutical-company Net Promoter Score recorded among U.S. healthcare providers in 2025.[47]

Customer retention in the biotechnology and pharmaceutical industry

  • 25% of visitors returned to healthcare-professional portals operated by pharmaceutical companies in 2024.[48]
  • 22% of pharmaceutical companies acted on insights related to healthcare-professional engagement in 2024.[48]
  • 24% of pharmaceutical companies analyzed healthcare-professional engagement data in 2024.[48]
  • 65% was the bounce rate for healthcare-professional portals operated by pharmaceutical companies in 2024.[48]

Customer acquisition in the biotechnology and pharmaceutical industry

  • 55% of pharmaceutical and healthcare advertising professionals identified brand advertising as a critical investment in 2024.[49]
  • 18% of pharmaceutical and healthcare advertising professionals identified demand generation as a critical media capability in 2023.[49]
  • 24% of pharmaceutical and healthcare advertising professionals identified demand generation as a critical media capability in 2024.[49]
  • 73% of pharmaceutical and healthcare advertising professionals identified performance-driven paid media as a critical investment in 2024.[49]

Lead generation in the biotechnology and pharmaceutical industry

  • 18% of pharmaceutical and healthcare advertising professionals ranked demand generation among their critical media capabilities in 2023.[49]
  • 24% of pharmaceutical and healthcare advertising professionals ranked demand generation among their critical media capabilities in 2024.[49]

09 Statistics

Marketing & Brand

Brand and digital engagement signals diverge, with a 0.1% pharmaceutical email click-through rate in the benchmark dataset.

Marketing in the biotechnology and pharmaceutical industry

  • 81% of drug-development-services companies developed an annual marketing plan in 2024.[50]
  • 81% of drug-development-services companies reported a clearly defined value proposition in marketing collateral in 2024.[50]
  • 64% of life-sciences respondent companies outsourced some or all marketing activity to an external agency in 2024.[50]
  • $10.9 million was the average marketing investment reported by biotech companies in 2023, up from $3.9 million in 2022.[51]
  • 40% of drug-development-services companies developed an annual public-relations or communications plan in 2024.[50]

Digital marketing in the biotechnology and pharmaceutical industry

  • 34.65% was the reported email open rate for medical, dental and healthcare marketing in the pharmaceutical digital-marketing benchmark source.[52]
  • More than 3% was the average engagement rate for pharmaceutical email campaigns sending healthcare professionals 10 to 15 emails in the analyzed dataset.[18]
  • 0.1% was the reported pharmaceutical email click-through rate in the pharmaceutical digital-marketing benchmark source.[52]
  • Less than 2% was the average engagement rate for pharmaceutical email campaigns sending healthcare professionals at least 16 emails in the analyzed dataset.[18]
  • 79% of U.S. healthcare professionals preferred efficacy-related content from pharmaceutical companies in Indegene’s survey.[10]

Branding in the biotechnology and pharmaceutical industry

  • $10.101 billion was Lilly’s pharmaceutical brand value in 2026.[53]
  • $5.927 billion was AstraZeneca’s pharmaceutical brand value in 2026.[53]
  • $7.610 billion was Roche’s pharmaceutical brand value in 2026.[53]
  • $119.9 billion was the combined brand value of the world’s 50 most valuable pharmaceutical brands in 2026.[53]
  • $17.713 billion was Johnson & Johnson’s pharmaceutical brand value in 2026.[53]

Social media in the biotechnology and pharmaceutical industry

  • 61% of U.S. prescribers ultimately prescribed a medication after a patient approached them about it from social media in 2025.[54]
  • 77% of U.S. prescribers were concerned about inappropriate prescribing when social-media-prompted medication requests were fulfilled in 2025.[54]
  • 68% of U.S. prescribers worried about losing patient trust if they declined a social-media-prompted prescription request in 2025.[54]
  • 57% of U.S. consumers said government regulation of prescription-drug promotion on social media was very or extremely important in 2025.[54]
  • 66% of U.S. consumers said pharmaceutical sponsorships on social media should be disclosed in 2025.[54]

Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)

  • 50% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their prescribing choices in 2024.[55]
  • 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[56]
  • 10% of healthcare and pharmaceutical marketers said they did not invest in creator or influencer marketing in 2026, globally.[57]
  • 50% of healthcare and pharmaceutical marketers reported dedicated and growing budgets for creator or influencer marketing in 2026, globally.[57]
  • 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[57]

10 Statistics

Operations & Execution

Execution timing remains a control point: the 2024 industry benchmark for time from Phase I through filing in biopharmaceutical development is 100.4 months.

Process optimization in the biotechnology and pharmaceutical industry

  • 260 days was the average time from identifying a protocol amendment need to final oversight approval across 950 pharmaceutical and CRO protocols.[58]
  • 100.4 months was the 2024 industry benchmark for time from Phase I through filing in biopharmaceutical development worldwide.[1]
  • 5.3 months was the 2024 average report-writing duration from database lock to clinical study report in biopharmaceutical R&D.[59]
  • 273 days was the 2022 median time in the United Kingdom from commercial clinical-trial application submission to first patient first dose.[60]
  • 112 days was the median clinical-trial setup time in the United Kingdom for the year ending March 2026.[61]

Operational efficiency in the biotechnology and pharmaceutical industry

  • 27% of small and mid-sized biopharmaceutical companies reported clinical-development timelines more than one year longer in 2024 than two years earlier.[6]
  • 81% of commercial collaborative studies in the United Kingdom were recruiting to time and target in April 2024.[60]
  • 86% of surveyed generic pharmaceutical sites reported they could reach full production within two years after repurposing idle capacity.[62]
  • 33% of large biopharmaceutical companies reported shorter clinical-development timelines in 2024 than two years earlier.[6]
  • 13.5% of surveyed U.S. pharmaceutical manufacturing sites operated below 30% utilization.[62]

Quality management in the biotechnology and pharmaceutical industry

  • 2012 was the year FDA received statutory authority to collect pharmaceutical manufacturing records and information for risk-based oversight.[25]
  • 2,412 FDA-registered active-pharmaceutical-ingredient manufacturing sites were identified across 57 countries in the latest available mapping.[63]
  • More than 90% of FDA pharmaceutical inspections found facilities with acceptable current good manufacturing practice compliance.[25]
  • 84.5% was the modeled normal utilization of quality-assurance and quality-control personnel in a 2026 vaccine-manufacturing disruption study.[64]
  • Nine establishments was the maximum number eligible for the FDA’s third 2026 Quality Management Maturity prototype cohort.[25]

Supply chain in the biotechnology and pharmaceutical industry

  • 22% of active-pharmaceutical-ingredient manufacturers were located in China in 2025.[25]
  • 69% of generic drug products distributed in the United States were manufactured outside the country in 2025.[25]
  • 44% of active-pharmaceutical-ingredient manufacturers were located in India in 2025.[25]
  • 50% of active-pharmaceutical-ingredient drug-master-file submissions filed with FDA cited Indian manufacturing facilities in 2023.[65]
  • 53% of brand drug products distributed in the United States were manufactured outside the country in 2025.[25]

Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)

  • 67% of global biotech and pharma companies outsourced pharmacovigilance operations in 2024, according to an IQVIA industry report.[2]
  • 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[6]
  • 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[6]
  • 40% of surveyed pharma and biotech CDMO decision-makers identified small-molecule API as the most outsourced product in July 2024.[66]
  • 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[2]

11 Statistics

Finance & Pricing

R&D and cost structures are central to industry economics: large R&D spending hit $190B in 2024, equal to 25.2% of sales.

Pricing strategy in the biotechnology and pharmaceutical industry

  • 53.3% was North America’s share of global prescription pharmaceutical sales at ex-factory prices in 2023.[67]
  • 67.3% was the manufacturer share of the average European retail medicine price in 2022.[67]
  • 22.7% was Europe’s share of global prescription pharmaceutical sales at ex-factory prices in 2023.[67]
  • 7.5% was China’s share of global prescription pharmaceutical sales at ex-factory prices in 2023.[67]
  • 17.0% was the pharmacist share of the average European retail medicine price in 2022.[67]

Cost reduction in the biotechnology and pharmaceutical industry

  • $11.7 million was MannKind’s increase in commercial-product gross profit in 2024 compared with 2023.[23]
  • 22% was MannKind’s increase in commercial-product gross profit in 2024, partly attributable to lower cost of goods sold and production efficiencies.[23]
  • $17.851 billion was Pfizer’s cost of sales in 2024.[23]
  • $14.9 million was West Pharmaceutical Services’ reduction in selling, general and administrative costs in 2024.[68]
  • 4.2% was West Pharmaceutical Services’ decrease in selling, general and administrative costs in 2024.[68]

Profitability in the biotechnology and pharmaceutical industry

  • $8.031 billion was Pfizer’s net income attributable to common shareholders in 2024.[23]
  • 36% was the average EBITDA margin of outperforming listed pharmaceutical and life-science companies from 2020 through 2023.[69]
  • $10.590 billion was Eli Lilly’s net income in 2024.[23]
  • $45.043 billion was Eli Lilly’s revenue in 2024.[23]
  • 15% was the increase in Merck’s pharmaceutical-segment profit in 2024 compared with 2023.[23]

Financial planning in the biotechnology and pharmaceutical industry

  • $14.730 billion was Pfizer’s selling, informational and administrative expense in 2024.[23]
  • $8.414 billion was Eli Lilly’s cost of sales in 2024.[23]
  • $121 billion was the estimated research-and-development expenditure of the 50 largest pharmaceutical companies in 2017.[61]
  • $10.822 billion was Pfizer’s research-and-development expense in 2024.[23]
  • $13.529 billion was Johnson & Johnson’s pharmaceutical research-and-development expense in 2024.[23]

12 Statistics

Product & Service

Service and patient support reach remains limited at scale, with only 3% of eligible patients engaging with pharmaceutical patient-support programs.

Product development in the biotechnology and pharmaceutical industry

  • 65 novel active substances launched globally in 2024, down from 80 in 2023.[2]
  • $102 billion was invested in biopharma research and development funding globally in 2024, excluding the pandemic-era peaks.[2]
  • $3.2 billion was the estimated capitalized R&D cost for medicines launched in 2020.[2]
  • Approximately 1% of compounds entering human trials ultimately generate a positive financial return.[2]
  • 66% of large biopharma companies surveyed were pursuing artificial intelligence in drug development, compared with 44% of small and midsize biopharma companies.[6]

Product lifecycle in the biotechnology and pharmaceutical industry

  • 46% of blockbuster sales in 2024 came from mega-blockbusters representing at least five times the annual blockbuster threshold.[2]
  • 63% of blockbusters were specialty medicines in 2024, compared with 5% of all blockbusters in 2000.[2]
  • 63% of global branded-medicine sales at list prices came from blockbuster medicines in 2024.[2]
  • 13.5 years was the average period from product launch to patent or other exclusivity expiry for U.S. biopharmaceutical products studied.[2]
  • 118 biologics are expected to lose patent protection in the United States between 2025 and 2034, representing $234 billion in potential loss-of-exclusivity opportunities.[2]

After-sales in the biotechnology and pharmaceutical industry

  • 10 to 20 vendors are managed per patient-support program, according to IQVIA’s analysis.[2]
  • 61% of patients found patient-support programs somewhat, a little, or not at all helpful.[2]
  • 46% of U.S. patient groups rated pharmaceutical companies positively for providing services beyond the pill in 2024.[70]
  • 60% of patients have little or no knowledge of pharmaceutical patient-support programs.[2]
  • Only 3% of eligible patients engage with pharmaceutical patient-support programs, according to IQVIA’s cited program analysis.[2]

Value proposition in the biotechnology and pharmaceutical industry

  • 57% of U.S. patient groups rated pharmaceutical companies positively for providing information in 2024.[70]
  • 77% of U.S. patient groups rated pharmaceutical companies positively for products that benefit patients in 2024.[70]
  • 38% of U.S. patient groups rated pharmaceutical companies positively for transparency of clinical data in 2024.[70]
  • 64% of U.S. patient groups rated pharmaceutical companies positively for ensuring patient safety in 2024.[70]
  • 49% of U.S. patient groups rated pharmaceutical companies positively for integrity in 2024.[70]

13 Statistics

Sustainability & Ethics

Sustainability in the biotechnology and pharmaceutical industry

  • 60% of life-sciences and pharmaceutical organizations published a sustainability report in 2025, according to a sector survey.[71]
  • 58% of surveyed life-sciences and pharmaceutical organizations covered responsible supply chains in their sustainability reporting in 2025.[71]
  • 53% of surveyed life-sciences and pharmaceutical organizations covered climate and carbon emissions in sustainability reporting in 2025.[71]
  • 62% of biopharma survey respondents identified sustainability as a top business priority for the next five years in 2024, globally.[72]
  • 68% of life-sciences and pharmaceutical executives considered ESG reporting requirements more of a cost than an opportunity in 2025.[71]

ESG in the biotechnology and pharmaceutical industry

  • 80 points was the 2024 average score for operation of governance bodies in the biotechnologies and pharmaceuticals sector.[73]
  • 66 points was the 2024 average cybersecurity score for the biotechnologies and pharmaceuticals sector.[73]
  • 701 patient groups from 74 countries participated in PatientView’s 2024 survey of pharmaceutical-industry ESG performance.[70]
  • 47 points was the 2024 average score for social characteristics and policies in the biotechnologies and pharmaceuticals sector.[73]
  • 60 points was the 2024 average business-ethics score for the biotechnologies and pharmaceuticals sector.[73]

Ethics in the biotechnology and pharmaceutical industry

  • 32% of FDA human-drug warning letters in 2025 concerned drug-manufacturing CGMP or adulteration violations in the United States.[25]
  • 55% of clinical trials subject to a U.S. results-reporting mandate were reported late or not at all, leaving 4,700 trials unpublished in the cited analysis.[74]
  • 44% of U.S. patient groups rated pharmaceutical-company clinical-data transparency in 2024, down from 51% in 2023.[70]
  • 38% of U.S. patient groups rated pharmaceutical-company clinical-data transparency in 2023 in PatientView’s comparison.[70]
  • 19% of FDA human-drug warning letters in 2025 concerned misleading advertising or promotion of compounded drugs in the United States.[25]

CSR in the biotechnology and pharmaceutical industry

  • 57 was the 2023 corporate-reputation score for pharmaceutical companies among U.S. patient groups.[70]
  • 61 was the 2024 corporate-reputation score for pharmaceutical companies among U.S. patient groups.[70]
  • More than 90 million people had been reached through AstraZeneca’s flagship access programmes by the end of 2024.[21]
  • 20 years of pharmaceutical-industry action on global health equity were covered by the 2026 Access to Medicine Index.[75]
  • 68 was the 2024 corporate-reputation score for biotechnology companies among U.S. patient groups.[70]

Circular economy in the biotechnology and pharmaceutical industry

  • 79.9 thousand metric tons of Pfizer hazardous waste were generated in 2024.[76]
  • 51.9 thousand metric tons of Pfizer hazardous waste were incinerated with energy recovery in 2024.[76]
  • 53 tonnes of AstraZeneca hazardous waste went to landfill in 2024.[21]
  • 12.6 thousand metric tons of Pfizer hazardous waste were diverted from disposal in 2024.[76]
  • 97% of AstraZeneca’s electricity consumption came from renewable sources under its RE100 metric in 2024.[21]

Carbon footprint in the biotechnology and pharmaceutical industry

  • 139,594 tonnes CO2e were AstraZeneca’s gross Scope 1 and 2 emissions in 2024.[21]
  • 3,751,482 tonnes CO2e were AstraZeneca’s 2024 Scope 3 emissions from purchased goods and services.[21]
  • 189,769 tonnes CO2e were AstraZeneca’s 2024 Scope 3 emissions from business travel.[21]
  • 80% of Novartis Scope 3 emissions came from purchased goods and services, according to its 2025 disclosure.[77]
  • 46% of AstraZeneca’s purchased-goods and capital-goods spend had supplier science-based targets in 2024.[21]

15 Statistics

Globalization & Expansion

Geographic sales concentration remains high: 51.8% of global pharmaceutical sales came from the United States in 2024.

Globalization in the biotechnology and pharmaceutical industry

  • 51.8% of global pharmaceutical sales came from the United States in 2024, compared with about 7% from China.[23]
  • Roche’s international pharmaceutical sales reached CHF9.691 billion in 2024, representing 21.0% of its pharmaceutical division sales.[87]
  • Pfizer supplied medicines and vaccines to approximately 200 countries and territories in 2024.[88]
  • 53.3% of worldwide pharmaceutical sales came from North America in 2023, while Europe accounted for 22.7%.[89]
  • China represented 4% of Pfizer’s total revenue in 2024, making it the company’s largest market outside the United States that year.[88]

Cultural adaptation in the biotechnology and pharmaceutical industry

  • Black participation in oncology approval trials reached at least 10% in only 6 of 99 approvals with reported race data.[24]
  • Asian participants represented approximately 7% of the U.S. population, a demographic benchmark highlighted in research on trial representation.[90]
  • 17% of clinical studies still failed to report race or ethnicity, or both, in 2024, down from more than 50% in 2009.[90]
  • Black participants represented 4% on average in cancer drug trials approved during 2017–2023, according to an analysis of 100 trials.[26]
  • White participants comprised more than 50% of the trial population for a majority of drug programs in the FDA’s 2024 review.[25]

Supplier management in the biotechnology and pharmaceutical industry

  • Agilent acquired BioVectra in September 2024; BioVectra operated biotechnology and pharmaceutical CDMO facilities at two Canadian sites.[29]
  • Biopharma-services M&A value increased to $24.2 billion in 2024 from $20.5 billion in 2023.[29]
  • Global biopharma-services M&A reached 272 transactions worth $24.2 billion in 2024.[29]
  • PharmaEssentia conducted annual review meetings with third-party logistics companies in 2024 to evaluate pharmaceutical trading operations and mechanisms.[34]
  • PharmaEssentia USA met Tier 1 suppliers every two weeks to discuss product-supply-chain risks in 2024.[34]

Stakeholder management in the biotechnology and pharmaceutical industry

  • 25% of surveyed U.S. patient groups reported active involvement in pharmaceutical R&D processes in 2024.[70]
  • 83% of surveyed U.S. patient groups reported receiving financial support from pharmaceutical companies in 2024.[70]
  • 11% of surveyed U.S. patient groups received pharmaceutical-company help with research in 2024.[70]
  • 37% of surveyed U.S. patient groups received pharmaceutical-company help with networking in 2024.[70]
  • 42% of surveyed U.S. patient groups said pharmaceutical companies co-created projects with them in 2024.[70]

Distribution channels in the biotechnology and pharmaceutical industry

  • Roche generated 19.1% of pharmaceutical-division sales in Europe in 2024.[87]
  • 19.0% of pharmaceutical distribution-industry sales went to mail-order fulfillment centers and other customers in 2024.[91]
  • 60.6% of pharmaceutical distribution-industry sales went to chain pharmacies, independent drug stores and specialty pharmacies in 2024.[91]
  • Pfizer’s products were distributed across approximately 200 countries and territories in 2024.[88]
  • Roche generated 53.7% of pharmaceutical-division sales in the United States in 2024.[87]

Key questions about the biotechnology and pharmaceutical industry

What is the biotechnology market size, and how fast is it expected to grow?
The global biotechnology market was estimated at $1.55 trillion in 2023. Grand View Research forecasts it reaching $3.88 trillion by 2030, a 13.96% CAGR from 2024 to 2030.
How are technology shifts showing up in biopharma operations and analytics adoption?
In 2026, 72% of operations and supply-chain leaders said AI automation increased reliance on real-time data. In 2025, 96% of commercial biopharma leaders said data was not well-structured or AI-ready for scaling.
Which companies lead the biotechnology and pharmaceutical industry?
Eli Lilly and Company leads Gitnux's 2026 biotechnology and pharmaceutical ranking with an Overall score of 9.8, with 2025 revenue reached $65.2 billion, driven by Mounjaro and Zepbound. Roche is the highest-ranked pharmaceuticals and diagnostics provider at 9.3, with 2025 group sales of CHF 61.5 billion across pharmaceuticals and diagnostics.
How is data governance framed in practical adoption terms (not just tools)?
Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024. Across 200 respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.
What does the industry’s market structure and regional sales footprint look like?
In 2024, the U.S. accounted for 54.8% of global drug sales, ahead of Europe, China and Japan. In Europe, the pharmaceutical market at factory prices was estimated at €295 billion in 2024, up from €274.5 billion in 2023.
What market signals point to dealmaking and commercialization pressure in 2025–2026?
Biopharma M&A rebounded in 2025, with 50 deals worth $133 billion, more than double the 2024 value. EY reported $240 billion in life-sciences M&A deals signed in 2025, with total value up 81% year over year.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 10). Biotechnology And Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/biotechnology-and-pharmaceutical-industry-statistics
MLA
Samuel Norberg. "Biotechnology And Pharmaceutical Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/biotechnology-and-pharmaceutical-industry-statistics.
Chicago
Samuel Norberg. 2026. "Biotechnology And Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/biotechnology-and-pharmaceutical-industry-statistics.

Sources & references

103 sources cited across this report

  1. deloitte.com
  2. iqvia.com
  3. pwc.com
  4. pmlive.com
  5. ispe.org
  6. ppd.com
  7. techresearchinfo.com
  8. test.benchling.com
  9. benchling.com
  10. insights.indegene.com
  11. within3.com
  12. medcitynews.com
  13. lazard.com
  14. digitalhealthcoalition.org
  15. veeva.com
  16. capgemini.com
  17. pistoiaalliance.org
  18. resources.indegene.com
  19. indegene.com
  20. link.springer.com
  21. astrazeneca.com
  22. mckinsey.com
  23. sec.gov
  24. pmc.ncbi.nlm.nih.gov
  25. fda.gov
  26. nature.com
  27. ey.com
  28. ropesgray.com
  29. corporatefinance.kpmg.com
  30. dealforma.com
  31. williamblair.com
  32. biospace.com
  33. pharmtech.com
  34. pharmaessentia.com
  35. innovatebio.org
  36. naceweb.org
  37. jthelander.com
  38. biobuzz.io
  39. massbio.org
  40. assets.kpmg.com
  41. amneal.com
  42. cultureamp.com
  43. bioindustry.org
  44. 4413123.fs1.hubspotusercontent-na1.net
  45. crowe.com
  46. acrpnet.org
  47. zs.com
  48. business.therounds.com
  49. s3.amazonaws.com
  50. scorrmarketing.com
  51. marketingcharts.com
  52. phamax-digital.ch
  53. brandirectory.com
  54. norc.org
  55. sermo.com
  56. jamanetwork.com
  57. brand-news.it
  58. pubmed.ncbi.nlm.nih.gov
  59. makingpharmaindustry.it
  60. gov.uk
  61. abpi.org.uk
  62. apicenter.org
  63. pharmatek.co.uk
  64. arxiv.org
  65. raps.org
  66. glginsights.com
  67. efpia.eu
  68. fintel.io
  69. rolandberger.com
  70. patient-view.com
  71. forvismazars.com
  72. cdn.cytivalifesciences.com
  73. static.seitosei-presse.com
  74. axios.com
  75. accesstomedicinefoundation.org
  76. cdn.pfizer.com
  77. novartis.com
  78. lifesciencesny.org
  79. acrohealth.org
  80. middlemarketcenter.org
  81. fortinet.com
  82. cpl.thalesgroup.com
  83. kiteworks.com
  84. etla.fi
  85. openpharma.blog
  86. insights.economistenterprise.com
  87. roche.com
  88. media.felix.fe.training
  89. assobiotec.federchimica.it
  90. bmjopenquality.bmj.com
  91. hda.org
  92. grandviewresearch.com
  93. healthaffairs.org
  94. fiercebiotech.com
  95. investor.lilly.com
  96. annualreport.novonordisk.com
  97. jnj.com
  98. sanofi.com
  99. investors.pfizer.com
  100. investors.abbvie.com
  101. bms.com
  102. bio.org
  103. cms.gov